Once-weekly (QW) apraglutide decreases parenteral support (PS) in short bowel syndrome with intestinal failure (SBS-IF) and colon-in-continuity (CIC)

Rationale: SBS-IF is a severe organ failure condition with life-long PS dependence. Glucagon-like peptide-2 (GLP-2) stimulates intestinal adaptation resulting in increased absorptive capacity of nutrients and fluids. Apraglutide (APRA) is a novel long-acting synthetic GLP-2 analog in development for SBS-IF. STARS Nutrition is a 52-W phase 2 study in adults with SBS-IF and CiC. This pre-defined interim analysis assesses safety and efficacy of QW subcutaneous APRA in reducing PS at 24W.
Source: Clinical Nutrition ESPEN - Category: Nutrition Authors: Source Type: research